

Thorax, CT scan
Vsevolod Zvirnyk / Science Photo Library

The 20th Annual
**John Vane
Memorial Symposium**

on Prostacyclin Science and
Pulmonary Vascular Disease

7th–8th March 2025

WHRL WILLIAM HARVEY
RESEARCH LIMITED | **CONFERENCES**

Foreword

Professor Chris Thiernemann FMedSci



Katharine Parmigiani, Chris Thiernemann, Brendan Whittle



Dear JVMS Friends and Colleagues,

It is my great honour to celebrate this **landmark John Vane Memorial Symposium** which is, as its title suggests, in its **20th year!** It is wonderful to welcome new attendees as well as the very many of you who have been an integral part of the *JVMS* community since the very beginning!

In 2006, it would have been difficult to imagine how successful the symposium series would become. The *JVMS* has evolved into one of the key dates in the annual calendar for those of you who work tirelessly to provide the very best treatment and care for patients with pulmonary hypertension (PH).

It is with heartfelt gratitude that I thank United Therapeutics for their unwavering support of this conference series though an educational grant. I would also like to acknowledge the global

commercial partners and delegates who continue to attend every year and, of course, our present and past illustrious speaker faculty without whom we would have been unable to deliver the most recent significant updates on pulmonary hypertension research, clinical practice and the very valued patient perspectives.

I am delighted to confirm that this year's scientific programme once again reflects the very latest developments in both research and treatment in PH. Highlights of the *JVMS-2025* Programme include presentations relating to the role of imaging and AI in the early diagnosis of PH, on pregnancy and PH and on the pathophysiology of methamphetamine-induced PH. We will also be reviewing novel clinical trial designs and endpoints in PH, and discuss both inhaled treprostinil and guanylate cyclase stimulators and activators for the treatment of PH. This year's programme concludes with a debate to seek a consensus on whether those patients with PH who present with a lung phenotype should be classified as WHO Group 1 or WHO Group 3.


As ever, I look forward to catching-up with you all and to hearing your thoughts on this year's programme alongside your memories of all the series to date.

I wish you a highly enjoyable and constructive time here in London.

With warmest regards,

Chris

Professor Chris Thiernemann MD PhD FBPhS FRCP FMedSci
Email: c.thiernemann@qmul.ac.uk



Friday, 7th March 2025

08.30-09.20 Registration, tea and coffee

09.20 **Welcome**
Chris Thiemermann, Queen Mary University of London, UK

Session I

Chairs: Chris Thiemermann, Queen Mary University of London, UK
Brendan Whittle, Queen Mary University of London, UK

09.30 **Hijacking the autonomic nervous system to improve health**
Gareth Ackland, Queen Mary University of London, UK

10.00 **Challenging the pulmonary circulation: why and how?**
Michele D'Alto, Mondali Hospital, Naples, Italy

10.30 Refreshments

Session II

Chairs: Hilary DuBrock, Mayo Clinic, Rochester, MN, USA
David Kiely, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

11.00 **Imaging and AI in the diagnosis and assessment of PH**
Andy Swift, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

11.30 **AI in the early diagnosis of PH**
Hilary DuBrock, Mayo Clinic, Rochester, MN, USA

12.00 **AI and early diagnosis of PH and ILD**
Tejaswini Kulkarni, University of Alabama, Birmingham, AL, USA

12.30 Lunch

Session III

Chairs: Michele D'Alto, Monaldi Hospital, Naples, Italy
Martin Kolb, McMaster University, Hamilton, Canada

14.00 **Novel mechanisms of ILD**
Katerina Antoniou, University of Crete, Heraklion, Crete, Greece

14.30 **Anti-fibrotic effects of Treprostinil**
Martin Kolb, McMaster University, Hamilton, Canada

15.00 **Inhaled Treprostinil in chronic lung diseases with or without PH: where do we stand?**
Chris King, Inova Fairfax Hospital, Falls Church, VA, USA

15.30 Refreshments

Session IV

Chairs: Irene Lang, Medical University of Vienna, Vienna, Austria
Marc Humbert, University of Paris-Saclay, Paris, France

16.00 **Future directions in pulmonary vascular disease: from bench to bedside**
Ardeschir Ghofrani, University of Giessen, Giessen, Germany

16.30 **Inhaled guanylate cyclase stimulators and activators for the treatment of pulmonary hypertension**
Marc Humbert, University of Paris-Saclay, Paris, France

17.00 **Methamphetamine-induced PH**
John Kingrey, Integris Health, Oklahoma City, OK, USA

17:30-18:30 Meeting adjournment and evening reception at the Royal Society

Saturday, 8th March 2025

08.30 Tea and coffee

Session V

Chairs: Ardeschir Ghofrani, University of Giessen, Giessen, Germany
Karen Olsson, University of Hannover, Hannover, Germany

09.30 **Novel clinical trial designs and endpoints in PH**
Jason Weatherald, University of Alberta, Edmonton, Canada

10.00 **Activin signalling inhibitors in PH**
Marius Hoyer, University of Hannover, Hannover, Germany

10.30 **Pregnancy and PH**
Karen Olsson, University of Hannover, Hannover, Germany

11.00 Refreshments

Session VI

Chairs: Marius Hoyer, University of Hannover, Hannover, Germany
Jason Weatherald, University of Alberta, Edmonton, Canada

11.30 **PH with lung phenotype: Is it WHO Group 1 or WHO Group 3?**

It is Group 1!

Stephen Mathai, Johns Hopkins University, Baltimore, MD, USA

It is Group 3!

Lucilla Piccari, Hospital Del Mar Medical Research Institute, Barcelona, Spain



12.30 Discussion


13.00 Lunch


14.00 Close of meeting



The John Vane Memorial Symposium Series 2006-2025







"In 2006, it would have been difficult to imagine how successful the symposium series would become."

Professor Chris Thiemermann



7th–8th March 2025

The Royal Society, London, UK

Faculty Chair

Chris Thiemermann, Queen Mary University of London, UK

Session Chairs:

Michele D'Alto

Monaldi Hospital, Naples, Italy

Hilary DuBrock

Mayo Clinic, Rochester, MN, USA

Ardeschir Ghofrani

University of Giessen, Giessen, Germany

Marius Hoepfer

University of Hannover, Hannover, Germany

Marc Humbert

University of Paris-Saclay, Paris, France

David Kiely

Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

Martin Kolb

McMaster University, Hamilton, Canada

Irene Lang

Medical University of Vienna, Vienna, Austria

Karen Olsson

University of Hannover, Hannover, Germany

Chris Thiemermann


Queen Mary University of London, UK

Jason Weatherald

University of Alberta, Edmonton, Canada

Brendan Whittle

Queen Mary University of London, UK



Thorax, CT scan
Vsevolod Zviryk / Science Photo Library

The 20th John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 8 category 1 (external) CPD credit(s).

William Harvey Research Limited

John Vane Science Centre
Charterhouse Square
London
EC1M 6BQ
United Kingdom
Tel: +44 (0)20 7882 8110
Email: whrl@qmul.ac.uk
www.williamharveyresearch.com

 @JVMSSeries

 @JVMSSeries

 @JVMSSeries